Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.54 USD | +2.74% | +8.65% | +68.88% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 800K | Capitalization | 673M |
---|---|---|---|---|---|
Net income 2024 * | -158M | Net income 2025 * | -241M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 841 x |
P/E ratio 2024 * |
-4.42
x | P/E ratio 2025 * |
-3.01
x | Employees | 157 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.3% |
Latest transcript on iTeos Therapeutics, Inc.
1 day | +0.84% | ||
1 week | +3.50% | ||
Current month | +68.06% | ||
1 month | +70.93% | ||
3 months | +82.51% | ||
6 months | +77.66% | ||
Current year | +64.84% |
Managers | Title | Age | Since |
---|---|---|---|
Michel Detheux
FOU | Founder | 57 | 12-03-31 |
Matthew Gall
DFI | Director of Finance/CFO | 47 | 20-05-31 |
Yvonne McGrath
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ann Rhoads
BRD | Director/Board Member | 58 | 20-05-31 |
David Hallal
CHM | Chairman | 57 | 18-05-31 |
Director/Board Member | 52 | 18-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.13% | 28 M€ | -0.48% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 18.49 | +2.45% | 108 381 |
24-05-17 | 18.05 | +0.84% | 344,183 |
24-05-16 | 17.9 | -0.33% | 425,624 |
24-05-15 | 17.96 | +7.42% | 629,779 |
24-05-14 | 16.72 | -1.76% | 778,824 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.84% | 673M | |
+9.42% | 115B | |
+11.84% | 106B | |
-2.18% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- ITOS Stock